Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Apogenix has reached the first milestone of its licensing agreement with CANbridge Life Sciences for the development and commercialization of lead immuno-oncology candidate APG101 in China, Macao, and Hong Kong.
Subscribe to our email newsletter
In addition, Apogenix and CANbridge have signed an amendment to expand the licensed territories to include Taiwan. Apogenix will continue to develop APG101 in all other territories.
An initial biomarker study conducted by CANbridge in Chinese glioblastoma patients revealed a high degree of CD95 ligand expression and confirmed the expression pattern seen in Apogenix’ phase II proof of concept trial in patients with recurrent glioblastoma.
APG101 is a CD95 ligand inhibitor which restores the immune response against tumors and inhibits invasive tumor cell growth. In Apogenix’ phase II trial, glioblastoma patients expressing a certain biomarker associated with the CD95 ligand experienced the greatest benefit from treatment with APG101.
The median overall survival rate in biomarker-positive patients treated with APG101 more than doubled to 16 months compared to patients treated with radiotherapy alone.
Apogenix CEO Thomas Hoeger said: "We are very pleased with CANbridge’s progress and the achievement of the first milestone ahead of schedule.
"Based on the commitment demonstrated by CANbridge and the excellent collaboration throughout our partnership, we have expanded the licensed territories to include Taiwan. We look forward to CANbridge initiating a phase I/II trial with APG101 in newly-diagnosed glioblastoma patients in Taiwan in the second half of this year."